Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.

NASDAQ:DRUG

Bright Minds Biosciences Inc.

Last Close

1.45

23/07 17:48

Market Cap

6.12M

Beta: 1.25

PE Ratio

−1.30

PFCF: −1.69

Institutional trades

Institutional Ownership

Current holdings institutionals